OIG Issues Report on Excluding 340B Drugs from Medicaid MCO Rebates

by Admin | June 14, 2016 12:53 pm

June 14, 2016—A new Department of Health and Human Services Office of Inspector General analysis of the ways states identify 340B drugs given to Medicaid managed care organization patients concludes that claim-level methods “can help states more accurately identify 340B claims, and thus reduce the risk of duplicate discounts and foregone rebates associated with provider-level-methods.”

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1]. Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:

Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2016/06/oig-issues-report-on-excluding-340b-drugs-from-medicaid-mco-rebates/